Kinase News and Research

RSS

Australian researchers develop safer and more effective aspirin

Monash University researchers and staff of the Melbourne-based biotechnology company Cerylid Biosciences Ltd, have discovered and developed a new class of anti-clotting drugs that appears to be more effective than aspirin at preventing disease-causing blood clots and has fewer side effects.

19 Apr 2005

New findings about insulin-signaling in the liver could prove useful in understanding type 2 diabetes

A collaborative effort led by The Burnham Institute's Gen-Sheng Feng has created a mouse with improved glucose tolerance and insulin activity in the liver, and generated new findings about insulin-signaling in the liver that could prove useful in understanding the pathogenesis of type 2 diabetes.

12 Apr 2005

Assessing the function of unknown genes is feasible and can be done with a microarray phenotype

Microarrays provide a method of quantifying the expression and order of genes in a particular genome -- acting as a surrogate measure of cell physiology, said researchers at Baylor College of Medicine in a report that appears online today in the journal Nature Genetics.

10 Apr 2005

Discovery could lead to new drug targets for heart disease

Mice with glowing green hearts have yielded the latest clue in the search for molecules involved in structural heart disease. Vanderbilt University Medical Center investigators found that blocking the activity of a single protein, called CaM kinase, in the mouse heart protects against the damaging effects of a heart attack.

30 Mar 2005

A circadian rhythm gene discovered

A few rare people who consistently nod off early, then wake up wide-eyed much before dawn, can blame a newly-found mutant gene for their sleep troubles, Howard Hughes Medical Institute researchers announced today.

30 Mar 2005

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Identifying the genetic malfunction that causes these disorders raises the hope that researchers may be able to devise a targeted therapy, just as they have done for chronic myelogenous leukemia (CML), which is presently treated with Gleevec. The three leukemias that share a common genetic cause are polycythemia vera (PV), essential thrombocythemia (ET) and myeloid metaplasia with myelofibrosis (MMM).

28 Mar 2005

Scientists provide insight into the molecular mechanisms behind Listeria monocytogenes

When the bacterium Listeria monocytogenes invades the body, it commandeers its host cell's actin cytoskeleton to invade other cells. In a report published in the Journal of Biological Chemistry, a group of scientists provide insight into the molecular mechanisms behind this infection technique.

21 Mar 2005

Molecule called DJ-1 is likely to be involved in the generation of human tumors

Scientists have discovered that a molecule called DJ-1 is likely to be involved in the generation of human tumors through negative regulation of the well-known tumor suppressor, PTEN. The research, published in the March issue of Cancer Cell, has important implications for determining the prognosis of some human cancers, and may prove to be a suitable target for cancer therapy.

14 Mar 2005

ViroLogic and AstraZeneca to conduct Iressa biomarker study

ViroLogic announced today that it had entered into an agreement with AstraZeneca to conduct a cancer biomarker study with application to Iressa, AstraZeneca's selective epidermal growth factor receptor kinase inhibitor.

7 Mar 2005

Novel role for cholesterol inside the cell

Cholesterol, often condemned for its role in heart disease, has always been known to be essential for the health of the fatty membranes that surround individual cells.

7 Mar 2005

Good side to cholesterol in controlling cell signals

Cholesterol, often stigmatized for its role in heart disease, has long been known to be essential for the health of the fat-laden membranes that surround individual cells.

6 Mar 2005

Discovery gives clinicians new targets for making existing therapies more effective and developing drugs to inhibit the growth of cancers

A team of researchers at the University of Alberta in Edmonton and the Samuel Lunenfeld Research Institute in Toronto have discovered how a key enzyme involved in repairing DNA is put together and how it works--a development that opens up new therapies for making cancer cells more vulnerable to attack.

3 Mar 2005

Novel mutation in the recently identified LRRK2 gene causes parkinsonism

Neuroscientists at Mayo Clinic in Jacksonville, Fla., leading a team of researchers in the United States and Europe, have discovered that a novel mutation in the recently identified LRRK2 gene causes parkinsonism in several North American and European families.

27 Feb 2005

New compound, AMN107, 20 times more potent than Gleevec for chronic myelogenous leukemia treatment

A laboratory study led by researchers at Dana-Farber Cancer Institute has shown that a potent and highly selective therapy for chronic myelogenous leukemia (CML) may ultimately be more effective than Gleevec®, the current standard of care.

21 Feb 2005

New compound AMN107 may help treat some imatinib resistant cancer cases

As scientists uncover the precise molecular mechanisms that underlie effective cancer treatments, they gain invaluable insight into why predominantly successful treatments fail for some patients.

14 Feb 2005

Special imaging study shows failing hearts are energy starved

Using magnetic resonance spectroscopy (MRS) for the first time to examine energy production biochemistry in a beating human heart, Johns Hopkins researchers have found substantial energy deficits in failing hearts.

7 Feb 2005

Plant protein mimics hormone that mitigates diabetes and obesity

A common protein that protects plants from fungal infection mimics the activity of a hormone in mammals that is linked to weight loss and is believed to play a role in mitigating heart disease, obesity and diabetes, according to a team of researchers at Purdue University and several collaborating institutions.

25 Jan 2005